Crinetics Pharmaceuticals, Inc. — Investor Relations & Filings

Crinetics Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. The company leverages its expertise in G-protein coupled receptors (GPCRs) to develop orally administered therapies aimed at addressing unmet medical needs. Its lead product candidate is paltusotine, an oral, nonpeptide somatostatin receptor type 2 (SST2) agonist for the treatment of acromegaly and carcinoid syndrome. The company's pipeline also includes atumelnant, an oral ACTH antagonist for conditions of excess cortisol such as congenital adrenal hyperplasia and Cushing's disease. Crinetics aims to build a leading endocrinology company by pioneering treatments that offer patients better disease control and greater convenience.